Adamas Pharmaceuticals Inc (ADMS):企業の財務・戦略的SWOT分析

◆英語タイトル:Adamas Pharmaceuticals Inc (ADMS) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C3054
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Adamas Pharmaceuticals Inc (ADMS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) is a pharmaceutical company that develops and commercializes therapeutics for chronic disorders of the central nervous system. The company’s Gocovri, formerly ADS-5102, is an amantadine extended-release (XR) formulation for the treatment for dyskinesia in patients with Parkinson’s disease. Gocovri is a high-dose, once-daily indication designed to deliver high level of amantadine in the morning and throughout the day when dyskinesia occurs. Its pipeline includes ADS-5102 for the treatment of wearing OFF, and delaying motor complications in Parkinson’s disease; Huntington’s chorea; tardive dyskinesia; non-motor disorders, including depression, and anti-psychotic induced weight gain; and Tourette syndrome; and various others indications; and ADS-4101 in Phase 3 for the treatment of partial onset seizures in patients with epilepsy. The company also offers namzaric and namenda XR for the treatment of moderate to severe Alzheimer’s disease. Adamas Pharmaceuticals is headquartered in Emeryville, California, the US.

Adamas Pharmaceuticals Inc Key Recent Developments

Aug 02,2018: Adamas announces second quarter 2018 financial results
May 03,2018: Adamas Reports First Quarter 2018 Financial Results
Feb 22,2018: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017
Nov 02,2017: Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results
Oct 11,2017: Adamas appoints Mardi C Dier to its board of directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Adamas Pharmaceuticals Inc – Key Facts 5
Adamas Pharmaceuticals Inc – Key Employees 6
Adamas Pharmaceuticals Inc – Major Products and Services 7
Adamas Pharmaceuticals Inc – History 8
Adamas Pharmaceuticals Inc – Company Statement 9
Adamas Pharmaceuticals Inc – Locations And Subsidiaries 11
Head Office 11
Section 2 – Company Analysis 12
Company Overview 12
Adamas Pharmaceuticals Inc – Business Description 13
R&D Overview 13
Adamas Pharmaceuticals Inc – Corporate Strategy 14
Adamas Pharmaceuticals Inc – SWOT Analysis 15
SWOT Analysis – Overview 15
Adamas Pharmaceuticals Inc – Strengths 15
Adamas Pharmaceuticals Inc – Weaknesses 16
Adamas Pharmaceuticals Inc – Opportunities 17
Adamas Pharmaceuticals Inc – Threats 18
Adamas Pharmaceuticals Inc – Key Competitors 19
Section 3 – Company Financial Ratios 20
Financial Ratios – Capital Market Ratios 20
Financial Ratios – Annual Ratios 21
Performance Chart 24
Financial Performance 24
Financial Ratios – Interim Ratios 25
Financial Ratios – Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Adamas Pharmaceuticals Inc, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
May 03, 2018: Adamas Reports First Quarter 2018 Financial Results 30
Feb 22, 2018: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017 31
Nov 02, 2017: Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results 33
Aug 08, 2017: Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results 35
Jun 28, 2017: Adamas Appoints New Chief Financial Officer 37
May 09, 2017: Adamas Reports Recent Achievements and First Quarter 2017 Financial Results 38
Apr 27, 2017: Adamas Pharmaceuticals appoints new COO 39
Feb 28, 2017: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016 40
Section 6 – Appendix 42
Methodology 42
Ratio Definitions 42
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Adamas Pharmaceuticals Inc, Key Facts 5
Adamas Pharmaceuticals Inc, Key Employees 6
Adamas Pharmaceuticals Inc, Major Products and Services 7
Adamas Pharmaceuticals Inc, History 8
Adamas Pharmaceuticals Inc, Key Competitors 19
Adamas Pharmaceuticals Inc, Ratios based on current share price 20
Adamas Pharmaceuticals Inc, Annual Ratios 21
Adamas Pharmaceuticals Inc, Annual Ratios (Cont...1) 22
Adamas Pharmaceuticals Inc, Annual Ratios (Cont...2) 23
Adamas Pharmaceuticals Inc, Interim Ratios 25
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Adamas Pharmaceuticals Inc, Recent Deals Summary 29
Currency Codes 42
Capital Market Ratios 42
Equity Ratios 43
Profitability Ratios 43
Cost Ratios 44
Liquidity Ratios 44
Leverage Ratios 45
Efficiency Ratios 45

List of Figures
Adamas Pharmaceuticals Inc, Performance Chart (2013 - 2017) 24
Adamas Pharmaceuticals Inc, Ratio Charts 26
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28

★海外企業調査レポート[Adamas Pharmaceuticals Inc (ADMS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Merz Pharma GmbH & Co. KGaA:企業のM&A・事業提携・投資動向
    Merz Pharma GmbH & Co. KGaA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Merz Pharma GmbH & Co. KGaA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • PT Dahana:企業の戦略・SWOT・財務情報
    PT Dahana - Strategy, SWOT and Corporate Finance Report Summary PT Dahana - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • JFE Holdings Inc (5411):企業の財務・戦略的SWOT分析
    JFE Holdings Inc (5411) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Xenon Pharmaceuticals Inc (XENE):製薬・医療:M&Aディール及び事業提携情報
    Summary Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that discovers and develops therapeutics for patients suffering with neurological disorders. The company's pipeline products include XEN1101, XEN901, XEN007 and GDC-0310. It discovers various valid …
  • Miromatrix Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Miromatrix Medical Inc (Miromatrix Medical) is a biotechnology company engaged in the development extracellular matrix based medical devices in soft tissue reinforcement and advanced wound care. The company offers MIRODERM a porcine liver-derived noncrosslinked acellular biologic wound matri …
  • Companhia Riograndense de Mineracao:企業の戦略・SWOT・財務情報
    Companhia Riograndense de Mineracao - Strategy, SWOT and Corporate Finance Report Summary Companhia Riograndense de Mineracao - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Cancer Genetics Inc (CGIX):医療機器:M&Aディール及び事業提携情報
    Summary Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic info …
  • NuVasive Inc (NUVA):製品パイプライン分析
    Summary NuVasive Inc (NuVasive) is a medical device company that provides minimally invasive, procedurally-integrated spine solutions. The company principally provides Maximum Access Surgery (MAS), a minimally-disruptive surgical platform. MAS platform enables surgeons to perform a range of minimall …
  • BioDot Inc-医療機器分野:企業M&A・提携分析
    Summary BioDot Inc (BioDot) is a healthcare products provider that manufactures low volumes of fluids and powder dispensing products. The company offers lateral flow, immunoblots, biojet, airjet, dry chemistry, bio chips, low volume PCR, glucose biosensors, biosensors, polyject and dispo powder disp …
  • St.George Bank:企業の戦略的SWOT分析
    St.George Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • 3M Co (MMM):電力:M&Aディール及び事業提携情報
    Summary 3M Company (3M) is a diversified technology company that specializes in the development, manufacture and marketing of a wide range of innovative products. The company develops technology platforms, including adhesives, abrasives, light management, microreplication, non woven materials, nanot …
  • Information Analysis Inc (IAIC):企業の財務・戦略的SWOT分析
    Summary Information Analysis Inc (IAI) is a technology company that offers technical solutions. The company offers IT services such as legacy mainframe modernization, database conversion and migration, electronic forms conversion, ebusiness and web based solutions, integrated tablet and mobile appli …
  • Fate Therapeutics Inc (FATE):企業の財務・戦略的SWOT分析
    Fate Therapeutics Inc (FATE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Petrus Resources Ltd (PRQ):石油・ガス:M&Aディール及び事業提携情報
    Summary Petrus Resources Ltd (Petrus Resources) is an energy company. The company operates in exploitation, strategic acquisitions, development, and risk-managed exploration of oil and gas properties in western Canada. It operates in the areas of Ferrier, Central Alberta, and the central Rocky Mount …
  • Tyme Technologies Inc (TYME):製薬・医療:M&Aディール及び事業提携情報
    Summary Tyme Technologies Inc (Tyme) is a clinical-stage pharmaceutical company. The company focused on discovering and developing targeted cancer therapeutics for oncology indications. It develops clinical program SM-88, an oral tyrosine-based therapy that is currently in Phase II development for p …
  • Surgutneftegas (SNGS):企業の財務・戦略的SWOT分析
    Surgutneftegas (SNGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Sartorius Stedim Biotech SA (DIM):企業の財務・戦略的SWOT分析
    Sartorius Stedim Biotech SA (DIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Pfizer Inc (PFE)-医療機器分野:企業M&A・提携分析
    Summary Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, …
  • Regeneron Pharmaceuticals Inc (REGN):企業の財務・戦略的SWOT分析
    Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Firstsource Solutions Ltd (FSL):企業の財務・戦略的SWOT分析
    Firstsource Solutions Ltd (FSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆